The psychedelic “Renaissance” is well underway, and yet access to psychedelic therapies are still highly restricted and unavailable to most patients. This panel of Canadian psychedelic researchers and business leaders will discuss obstacles to access and how to overcome them, with a focus on current and upcoming studies and product development, regulatory changes, and evidence-based psychedelic-assisted treatments.
Moderated by Phillipe Lucas, PhD
